Boothbay Fund Management LLC Trims Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Boothbay Fund Management LLC reduced its position in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 52.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 181,042 shares of the company's stock after selling 201,674 shares during the period. Boothbay Fund Management LLC owned about 0.30% of Pyxis Oncology worth $282,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. American Century Companies Inc. grew its holdings in shares of Pyxis Oncology by 88.1% during the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company's stock worth $468,000 after purchasing an additional 140,498 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Pyxis Oncology by 83.0% during the fourth quarter. Renaissance Technologies LLC now owns 293,354 shares of the company's stock worth $458,000 after acquiring an additional 133,018 shares during the last quarter. Aristides Capital LLC acquired a new position in Pyxis Oncology in the fourth quarter valued at approximately $193,000. Sei Investments Co. bought a new stake in shares of Pyxis Oncology during the fourth quarter worth $95,000. Finally, Geode Capital Management LLC grew its holdings in shares of Pyxis Oncology by 5.5% during the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company's stock worth $3,982,000 after buying an additional 57,016 shares in the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PYXS. HC Wainwright reissued a "buy" rating and issued a $5.00 price objective on shares of Pyxis Oncology in a research report on Wednesday, March 19th. Royal Bank of Canada reissued an "outperform" rating and issued a $8.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, March 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $9.00.

Pyxis Oncology Trading Up 2.3 %

Shares of PYXS stock traded up $0.03 during trading on Thursday, hitting $1.10. The company's stock had a trading volume of 216,080 shares, compared to its average volume of 734,387. The business has a fifty day moving average of $1.05 and a 200-day moving average of $1.77. Pyxis Oncology, Inc. has a 52 week low of $0.83 and a 52 week high of $5.39. The company has a market cap of $67.83 million, a PE ratio of -1.06 and a beta of 1.15.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.01. The firm had revenue of $16.15 million during the quarter. As a group, research analysts predict that Pyxis Oncology, Inc. will post -1.04 EPS for the current year.

Pyxis Oncology Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.